Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam Inc (BEAT) pioneers portable cardiac monitoring solutions through its credit card-sized ECG device and AI-driven diagnostic platform. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in remote cardiology technology.
Access authoritative reporting on regulatory milestones, clinical study results, and strategic partnerships shaping the future of telehealth diagnostics. Our curated collection includes earnings reports, product launch announcements, and peer-reviewed research validations, including studies conducted with Harvard Medical School faculty.
Key updates cover developments in Vector ECG technology, FDA clearance progress, and AI algorithm enhancements that improve cardiac event detection accuracy. Bookmark this page to stay informed about innovations bridging hospital-grade diagnostics with at-home healthcare solutions.
HeartBeam (NASDAQ: BEAT) reported Q3 2024 financial results, highlighting progress on its cardiac care technology. The company's FDA 510(k) submission for the HeartBeam system is under active review, with successful responses to FDA questions. Financial results show R&D expenses of $2.9M vs $1.6M in Q3 2023, and net loss of $5.0M vs $3.5M in Q3 2023. Cash position stands at $5.8M as of September 30, 2024. Key management appointments include Robert Eno as CEO, Dr. Branislav Vajdic as President, Tim Cruickshank as CFO, and Dr. Lance Myers as Chief AI Scientist.
HeartBeam (NASDAQ: BEAT) has announced its upcoming Q3 2024 earnings conference call scheduled for November 7, 2024, at 4:30 p.m. Eastern time. The call will feature CEO Robert Eno, Founder and President Branislav Vajdic, and CFO Timothy Cruickshank discussing third quarter results, regulatory updates, ongoing initiatives, and anticipated milestones. A press release with detailed results will be issued before the call. The presentation will be accessible via webcast and the company's investor relations website. A replay will be available until February 7, 2025.
HeartBeam (NASDAQ: BEAT) has been named a Rising Star in the 'Home Health Diagnostic' category at the 2024 Digital Health Hub Foundation Awards. The recognition was presented during the HLTH global healthcare conference for the company's innovative vector-based technology that captures heart electrical signals in three dimensions. The company's first application is a cable-free, credit card-sized device designed to synthesize a 12-lead ECG, currently under FDA review. HeartBeam holds 13 US patents and 4 international patents for its technology, which aims to provide comprehensive cardiac insights by leveraging AI analysis.
HeartBeam (NASDAQ: BEAT) has appointed Robert Eno as Chief Executive Officer, effective October 21, 2024. Eno, who joined as President in January 2023, will lead the company's efforts to secure FDA 510(k) clearance for its vector-based technology and prepare for commercialization. Founder and current CEO Branislav Vajdic will transition to the role of President, focusing on innovation, R&D, and advancing AI applications.
HeartBeam's core technology captures the heart's electrical signals in three dimensions, providing total heart intelligence. The company's first application is a cable-free, credit card-sized device designed to synthesize a 12-lead ECG, currently under FDA review. HeartBeam holds 13 U.S. patents and 4 international patents for its technology.
Eno brings over 30 years of experience in developing go-to-market strategies for breakthrough medical products. He previously served as CEO of Preview Medical and held senior roles at HeartFlow, OptiMedica, and other medical technology companies.
HeartBeam (NASDAQ: BEAT) has appointed Dr. Lance Myers as Chief AI Scientist to drive innovation in its cardiac care technology. Dr. Myers, formerly Head of Data Science at Verily (Google Life Sciences), will guide AI application to HeartBeam's core technology. The company's vector-based approach combined with AI has shown equivalent performance to a 12-lead ECG and improved detection of atrial flutter over single-lead ECG.
HeartBeam's technology captures heart signals in three dimensions, with its first application being a cable-free, credit card-sized device capable of synthesizing a 12-lead ECG. The system is under FDA review. The company aims to leverage AI for improved diagnostic accuracy and personalized cardiac care, analyzing longitudinal data from patient device usage.
HeartBeam (NASDAQ: BEAT) has appointed Timothy Cruickshank as its new Chief Financial Officer, effective immediately. Cruickshank brings over 15 years of public company experience, focusing on growing businesses with disruptive technologies. He succeeds Richard Brounstein, who retired in February.
HeartBeam has developed a cable-free, credit card-sized device that captures the heart's electrical signals in three dimensions, capable of synthesizing a 12-lead ECG. The company's first 510(k) submission for this proprietary technology is currently under FDA review. HeartBeam holds 13 US patents and 4 international patents supporting the technology.
Cruickshank, 43, previously served as CFO at ImpediMed, where he led the company's transformation from a traditional medical device company to a medical technology company with a high-margin SaaS business model.
HeartBeam (NASDAQ: BEAT) reported Q2 2024 results, highlighting progress on its HeartBeam AIMIGo™ System. Key developments include:
1. FDA review of AIMIGo 510(k) submission ongoing, with most questions resolved.
2. Completed enrollment for VALID-ECG clinical study.
3. Presented new data on HeartBeam AI at EHRA and HRS conferences.
4. Won 'Best New ECG Technology Solution' award.
5. Added to Russell Microcap® Index.
Financial results: R&D expenses $2.8M, G&A expenses $2.2M, net loss $5.0M. Cash position: $9.2M as of June 30, 2024. The company anticipates FDA clearance and AIMIGo launch by end of 2024.
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has announced its upcoming second quarter 2024 results conference call. The call is scheduled for Wednesday, August 14, 2024, at 4:30 p.m. Eastern time. CEO Branislav Vajdic, President Robert Eno, and Senior Director & Corporate Controller Ravi Malhotra will host the call, which will include discussions on Q2 results, regulatory updates, ongoing initiatives, and anticipated 2024 milestones.
A press release detailing the results will be issued before the call. Investors can access the call via phone or webcast, with a presentation available during the webcast and on the company's investor relations website. A replay of the call will be available until November 14, 2024.
HeartBeam, a medical technology company specializing in cardiac care, announced its addition to the Russell Microcap® Index. This inclusion is effective post-market close on June 28, 2024, following the FTSE Russell’s annual reconstitution, which ranks the 4,000 largest US stocks by market capitalization as of April 30. Being part of the Russell Microcap® Index, which lists the smallest 1,000 securities in the Russell 2000® Index plus the next 1,000 smallest eligible securities, provides HeartBeam with enhanced visibility and potential accessibility to $10.5 trillion in assets benchmarked against these indexes. The Russell indexes serve as key benchmarks for investment managers and institutional investors.
Epitel, a pioneer in AI-powered brain health solutions, has announced the appointment of Ken Nelson to its Board of Directors. Nelson, an expert in digital health and remote patient monitoring, brings over 20 years of experience to Epitel. He has held key positions in leading companies such as BioTelemetry, iRhythm, and Bardy Diagnostics, with notable achievements including BioTelemetry's $2.8 billion acquisition by Philips and Bardy Diagnostics' $450 million acquisition by HillRom/Baxter. As Epitel strives to revolutionize brain monitoring with AI and wearable EEG technology, Nelson's strategic insight is expected to drive the company's growth and commercial success. He currently holds influential positions in several MedTech startups and advisory boards.
